Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma (HIMALAYA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03298451
Recruitment Status : Recruiting
First Posted : October 2, 2017
Last Update Posted : April 29, 2022
Information provided by (Responsible Party):

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Actual Primary Completion Date : August 27, 2021
Estimated Study Completion Date : August 27, 2024